What pharmaceutical-grade and purity claims actually document

Locate the actual claim and the material it describes

The current Bounce Back offer uses pharmaceutical-grade wording and discusses higher purity and bioavailability. It also advertises copper peptide at 2%. These are statements from the seller. The reviewed record does not supply this publication with an independently verified analytical specification or comparative report that settles those descriptions for a supplied preparation. Current Bounce Back offer

The CoreAge evidence review therefore keeps the claims attributed. An unclear public specification is not proof of a defective product; equally, an impressive phrase is not proof that a particular test was passed. The missing document should remain a missing document.

Separate identity from purity and concentration

Identity concerns which substance is being described. Concentration concerns its stated proportion within a preparation. Purity concerns the composition of the material being characterized. A percentage printed next to a broad copper-peptide name does not, by itself, answer all three questions or identify the analytical method behind them.

NIOD describes 1% GHK-Cu and an additional 1% GHK, while The Ordinary names a 1% copper-peptide serum with several other ingredients. Those records use their own terminology. The NIOD review and Ordinary review do not turn their descriptions into a shared purity scale. NIOD and The Ordinary

Ask what was tested rather than assume a universal certificate

A useful inquiry asks whether supporting information concerns an ingredient before formulation, the finished preparation or another product entirely. It also asks what property the record assessed and whether it identifies the relevant version or batch. These are documentation questions, not a claim that we obtained or authenticated such a report.

A test addressing one property would not automatically establish every other quality or clinical claim. For example, a record identifying a component would not alone demonstrate comparative skin absorption or visible firmness. This guide does not invent a universal testing checklist, declare a pharmacy compliant or set a clinical passing score from incomplete public information.

The report also needs a clear connection to the item being discussed. A document about a raw material does not automatically describe the final cream, its other ingredients or its performance after formulation.

Do not equate a prescription pathway with FDA approval

CoreAge describes Bounce Back as compounded, and the current offer acknowledges that it is not FDA-approved. FDA explains that compounded drugs do not receive its premarket verification of safety, effectiveness and quality. A prescription assessment and a pharmacy-prepared product therefore do not establish approval of this exact finished cream. FDA compounding explanation

That distinction does not amount to an inspection finding about a particular compounder. FDA also describes different oversight arrangements for different compounding settings. Without an identified preparation and appropriate records, a review cannot infer that a seller's quality language proves either regulatory compliance or a regulatory violation.

Cosmetic status answers a different question

FDA generally does not preapprove cosmetic products or ingredients, with an important exception for certain color additives. Cosmetic companies remain responsible for safe, properly labeled products, and current law includes safety-substantiation responsibilities. The lack of ordinary cosmetic preapproval should not be rewritten as an automatic finding that a serum is unsafe. FDA cosmetics explanation

The source comparison keeps this framework separate from the compounded prescription offer. Neither category establishes which product is clinically superior. Intended use, the actual claim and the relevant evidence matter; a quality adjective cannot erase the distinctions between cosmetics, compounded preparations and approved drugs.

Delivery and visible results need their own support

A claim of higher bioavailability requires more than a high-looking ingredient percentage to be interpretable. The reader needs to know what was compared, what was measured and whether the tested preparation matches the offered one. The reviewed Bounce Back records do not provide a verified head-to-head delivery study that answers those questions.

Nor would a delivery finding automatically establish the greatest visible improvement in every person. The firmness-claims guide separates feeling, appearance and proposed mechanism. The study-endpoint guide shows why even results within one small study must retain their actual outcome definitions.

Use a question that the source can answer

A focused question asks which specification supports the grade claim, what product or material it concerns and which conclusions the report does not address. If the answer supplies only a general ingredient explanation, that may be useful context but does not become evidence of the exact finished preparation's comparative performance.

The fixed claim reader makes that distinction visible without assigning a quality score. The price guide then treats cost as a separate record. Paying more, obtaining a prescription or reading a scientific-sounding phrase cannot substitute for knowing precisely what has been documented and what has not been verified.